Metabolomics: A novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease

Neuroscience Bulletin

Volumn 28, Issue 5, 2012, Pages 641-648

  Xu, Xu Hua ^a   Huang, Yue ^b   Wang, Gang ^a   Chen, Sheng Di ^a,c  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; Biomarkers; Metabolomics

Indexed keywords

CHOLESTEROL; MONOAMINE;

ALZHEIMER DISEASE; ANALYTIC METHOD; CAPILLARY ELECTROPHORESIS; CHOLESTEROL BLOOD LEVEL; DISEASE MARKER; ELECTROCHEMICAL ANALYSIS; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; HUMAN; LIPIDOMICS; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PATHOPHYSIOLOGY; REVIEW; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; HUMANS; METABOLOMICS;

EID: 84871407901     PISSN: 16737067     EISSN: 19958218     Source Type: Journal    
DOI: 10.1007/s12264-012-1272-0     Document Type: Review

References (48)

1. Prince M, Jackson J. Alzheimer's Disease International. World Alzheimer Report 2009.
2. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 2011, 7: 137-152.
3. Mayeux R, Reitz C, Brickman AM, Haan MN, Manly JJ, Glymour MM, et al. Operationalizing diagnostic criteria for Alzheimer's disease and other age-related cognitive impairment-Part 1. Alzheimers Dement 2011, 7: 15-34.
4. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 2011, 95: 594-600.
5. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7: 257-262.
6. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010, 9: 702-716.
7. Herholz K, Ebmeier K. Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011, 10: 667-670.
8. Li TQ, Wahlund LO. The search for neuroimaging biomarkers of Alzheimer's disease with advanced MRI techniques. Acta Radiol 2011, 52: 211-222.
9. Humpel C. Identifying and validating biomarkers for Alzheimer'sdisease. Trends Biotechnol 2011, 29: 26-32.
10. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet 2011, 377: 1019-1031.
11. Herrup K. Reimagining Alzheimer's disease-an age-based hypothesis. J Neurosci 2010, 30: 16755-16762.
12. Agnati LF, Guidolin D, Baluska F, Leo G, Barlow PW, Carone C, et al. A new hypothesis of pathogenesis based on the divorce between mitochondria and their host cells: possible relevance for Alzheimer's disease. Curr Alzheimer Res 2010, 7: 307-322.
13. Qiu C, Xu W, Fratiglioni L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. J Alzheimers Dis 2010, 20: 689-697.
14. Li J, Wang YJ, Zhang M, Xu ZQ, Gao CY, Fang CQ, et al. Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease. Neurology 2011, 76: 1485-1491.
15. Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 2011, 236: 772-782.
16. Wang JH, Byun J, Pennathur S. Analytical approaches to metabolomics and applications to systems biology. Semin Nephrol 2010, 30: 500-511.
17. Gomase VS, Changbhale SS, Patil SA, Kale KV. Metabolomics. Curr Drug Metab 2008, 9: 89-98. (Pubitemid 351201675)
18. Ganti S, Weiss RH. Urine metabolomics for kidney cancer detection and biomarker discovery. Urol Oncol 2011, 29: 551-557.
19. Bernini P, Bertini I, Luchinat C, Tenori L, Tognaccini A. The cardiovascular risk of healthy individuals studied by NMR metabonomics of plasma samples. J Proteome Res 2011, 10: 4983-4992.
20. Bathen TF, Sitter B, Sjobakk TE, Tessem MB, Gribbestad IS. Magnetic resonance metabolomics of intact tissue: a biotechnological tool in cancer diagnostics and treatment evaluation. Cancer Res 2010, 70: 6692-6696.
21. Benahmed MA, Santelmo N, Elbayed K, Frossard N, Noll E, Canuet M, et al. The assessment of the quality of the graft in an animal model for lung transplantation using the metabolomics (1) H highresolution magic angle spinning NMR spectroscopy. Magn Reson Med 2011, doi: 10.1002/mrm.24110.
22. Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst 2012, 137: 293-300.
23. Koek MM, Jellema RH, van der Greef J, Tas AC, Hankemeier T. Quantitative metabolomics based on gas chromatography mass spectrometry: status and perspectives. Metabolomics 2011, 7: 307-328.
24. Zhou B, Xiao JF, Tuli L, Ressom HW. LC-MS-based metabolomics. Mol Biosyst 2012, 8: 470-481.
25. Wang X, Sun H, Zhang A, Wang P, Han Y. Ultra-performance liquid chromatography coupled to mass spectrometry as a sensitive and powerful technology for metabolomic studies. J Sep Sci 2011, 34: 3451-3459.
26. Barbas C, Moraes EP, Villasenor A. Capillary electrophoresis as a metabolomics tool for non-targeted fingerprinting of biological samples. J Pharm Biomed Anal 2011, 55: 823-831.
27. Ludwig C, Viant MR. Two-dimensional J-resolved NMR spectroscopy: review of a key methodology in the metabolomics toolbox. Phytochem Anal 2010, 21: 22-32.
28. Koek MM, van der Kloet FM, Kleemann R, Kooistra T, Verheij ER, Hankemeier T. Semi-automated non-target processing in GC x GC-MS metabolomics analysis: applicability for biomedical studies. Metabolomics 2011, 7: 1-14.
29. Gokay O, Albert K. From single to multiple microcoil flow probe NMR and related capillary techniques: a review. Anal Bioanal Chem 2012, 402: 647-669.
30. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008, 131: 389-396. (Pubitemid 351197614)
31. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC. A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 2007, 22: 418-423. (Pubitemid 46831684)
32. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, et al. Potential metabolite markers of schizophrenia. Mol Psychiatry 2011, doi: 10.1038/mp.2011.131.
33. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001, 276: 21562-21570. (Pubitemid 37413154)
34. Higgins LS, Catalano R, Quon D, Cordell B. Transgenic mice expressing human beta-APP751, but not mice expressing beta- APP695, display early Alzheimer's disease-like histopathology. Ann N Y Acad Sci 1993, 695: 224-227. (Pubitemid 23348265)
35. Salek RM, Xia J, Innes A, Sweatman BC, Adalbert R, Randle S, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 2010, 56: 937-947.
36. Koch G, Esposito Z, Codeca C, Mori F, Kusayanagi H, Monteleone F, et al. Altered dopamine modulation of LTD-like plasticity in Alzheimer's disease patients. Clin Neurophysiol 2011, 122: 703-707.
37. Madsen K, Neumann WJ, Holst K, Marner L, Haahr MT, Lehel S, et al. Cerebral serotonin 4 receptors and amyloid-beta in early Alzheimer's disease. J Alzheimers Dis 2011, 26: 457-466.
38. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, et al. Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 2011, 7: 309-317.
39. Han X. Lipid alterations in the earliest clinically recognizable stage of Alzheimer's disease: implication of the role of lipids in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2005, 2: 65-77. (Pubitemid 41389260)
40. Mielke MM, Bandaru VV, Haughey NJ, Rabins PV, Lyketsos CG, Carlson MC. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol Aging 2010, 31: 17-24.
41. Li NJ, Liu WT, Li W, Li SQ, Chen XH, Bi KS, et al. Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/ mass spectrometry. Clin Biochem 2010, 43: 992-997.
42. Wenk MR. Lipidomics: new tools and applications. Cell 2010, 143: 888-895.
43. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, et al. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011, 6: e21643.
44. Wang DC, Sun CH, Liu LY, Sun XH, Jin XW, Song WL, et al. Serum fatty acid profiles using GC-MS and multivariate statistical analysis: potential biomarkers of Alzheimer's disease. Neurobiol Aging 2012, 33: 1057-1066.
45. Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch Neurol 2011, 68: 1239-1244.
46. Tukiainen T, Tynkkynen T, Makinen VP, Jylanki P, Kangas A, Hokkanen J, et al. A multi-metabolite analysis of serum by 1H NMR spectroscopy: early systemic signs of Alzheimer's disease. Biochem Biophys Res Commun 2008, 375: 356-361.
47. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292: 2237-2242. (Pubitemid 39473161)
48. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, et al. HMDB: the Human Metabolome Database. Nucleic Acids Res 2007, 35: D521-526. (Pubitemid 46056263)